The Arp2/3 Inhibitory Protein Arpin Is Required for Intestinal Epithelial Barrier Integrity.

ZO-1 actin cytoskeleton colitis inflammatory bowel diseases intestinal barrier mesalazine (5-aminosalicylic acid) tight junction ulcerative colitis

Journal

Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250

Informations de publication

Date de publication:
2021
Historique:
received: 03 11 2020
accepted: 17 03 2021
entrez: 20 5 2021
pubmed: 21 5 2021
medline: 21 5 2021
Statut: epublish

Résumé

The intestinal epithelial barrier (IEB) depends on stable interepithelial protein complexes such as tight junctions (TJ), adherens junctions (AJ), and the actin cytoskeleton. During inflammation, the IEB is compromised due to TJ protein internalization and actin remodeling. An important actin regulator is the actin-related protein 2/3 (Arp2/3) complex, which induces actin branching. Activation of Arp2/3 by nucleation-promoting factors is required for the formation of epithelial monolayers, but little is known about the relevance of Arp2/3 inhibition and endogenous Arp2/3 inhibitory proteins for IEB regulation. We found that the recently identified Arp2/3 inhibitory protein arpin was strongly expressed in intestinal epithelial cells. Arpin expression decreased in response to tumor necrosis factor (TNF)α and interferon (IFN)γ treatment, whereas the expression of gadkin and protein interacting with protein C-kinase α-subunit 1 (PICK1), other Arp2/3 inhibitors, remained unchanged. Of note, arpin coprecipitated with the TJ proteins occludin and claudin-1 and the AJ protein E-cadherin. Arpin depletion altered the architecture of both AJ and TJ, increased actin filament content and actomyosin contractility, and significantly increased epithelial permeability, demonstrating that arpin is indeed required for maintaining IEB integrity. During experimental colitis in mice, arpin expression was also decreased. Analyzing colon tissues from ulcerative colitis patients by Western blot, we found different arpin levels with overall no significant changes. However, in acutely inflamed areas, arpin was significantly reduced compared to non-inflamed areas. Importantly, patients receiving mesalazine had significantly higher arpin levels than untreated patients. As arpin depletion (theoretically meaning more active Arp2/3) increased permeability, we wanted to know whether Arp2/3 inhibition would show the opposite. Indeed, the specific Arp2/3 inhibitor CK666 ameliorated TNFα/IFNγ-induced permeability in established Caco-2 monolayers by preventing TJ disruption. CK666 treatment also attenuated colitis development, colon tissue damage, TJ disruption, and permeability in dextran sulphate sodium (DSS)-treated mice. Our results demonstrate that loss of arpin triggers IEB dysfunction during inflammation and that low arpin levels can be considered a novel hallmark of acute inflammation.

Identifiants

pubmed: 34012961
doi: 10.3389/fcell.2021.625719
pmc: PMC8128147
doi:

Types de publication

Journal Article

Langues

eng

Pagination

625719

Informations de copyright

Copyright © 2021 Chánez-Paredes, Montoya-García, Castro-Ochoa, García-Cordero, Cedillo-Barrón, Shibayama, Nava, Flemming, Schlegel, Gautreau, Vargas-Robles, Mondragón-Flores and Schnoor.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Cell Biol. 2013 Apr 29;201(3):449-65
pubmed: 23629967
Clin Immunol. 2008 Jan;126(1):67-80
pubmed: 17964857
Int J Mol Sci. 2020 Feb 03;21(3):
pubmed: 32028590
Dev Cell. 2018 Feb 5;44(3):297-312.e5
pubmed: 29408236
Nat Cell Biol. 2008 Mar;10(3):259-71
pubmed: 18297063
Am J Physiol Gastrointest Liver Physiol. 2009 May;296(5):G1140-9
pubmed: 19221015
Sci Rep. 2018 Nov 2;8(1):16241
pubmed: 30389960
Sci Signal. 2014 Dec 02;7(354):rs7
pubmed: 25468996
J Cell Mol Med. 2016 Mar;20(3):450-8
pubmed: 26648569
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):E3820-9
pubmed: 24043783
Cell Mol Life Sci. 2019 Sep;76(17):3349-3361
pubmed: 31073744
Mol Biol Cell. 2015 Jun 1;26(11):1995-2004
pubmed: 25833710
J Immunol. 2003 Dec 1;171(11):6164-72
pubmed: 14634132
Cell. 2012 Mar 2;148(5):973-87
pubmed: 22385962
Mol Biol Cell. 2007 Mar;18(3):721-31
pubmed: 17182847
Curr Biol. 2008 Nov 11;18(21):1631-8
pubmed: 18976918
Biomed Pharmacother. 2017 Aug;92:116-121
pubmed: 28531800
EMBO Rep. 2020 Jan 7;21(1):e47963
pubmed: 31721415
J Cell Biol. 2011 Mar 21;192(6):907-17
pubmed: 21422226
Am J Pathol. 2005 Feb;166(2):409-19
pubmed: 15681825
Mol Biol Cell. 2015 Aug 1;26(15):2769-87
pubmed: 26063734
Biostat Bioinforma Biomath. 2013 Aug;3(3):71-85
pubmed: 25558171
Am J Physiol Gastrointest Liver Physiol. 2018 Mar 1;314(3):G408-G417
pubmed: 29351397
Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10382-7
pubmed: 22689987
J Biol Chem. 2013 Nov 15;288(46):33324-34
pubmed: 24081143
Mol Biol Cell. 2014 Sep 15;25(18):2710-9
pubmed: 25031428
Physiol Rev. 2018 Jan 1;98(1):215-238
pubmed: 29212790
Mol Biol Cell. 2009 Sep;20(17):3930-40
pubmed: 19605556
Science. 2014 Oct 31;346(6209):1254211
pubmed: 25359979
PLoS One. 2011 Apr 08;6(4):e18392
pubmed: 21494665
Mol Biol Cell. 2014 Jan;25(2):245-56
pubmed: 24227887
Nature. 2009 Aug 20;460(7258):1031-4
pubmed: 19648907
Microvasc Res. 2008 Nov;76(3):202-7
pubmed: 18657550
Nucleic Acids Res. 2012 Jan;40(Database issue):D261-70
pubmed: 22135298
Cell Res. 2019 Jun;29(6):432-445
pubmed: 30971746
Nat Rev Mol Cell Biol. 2013 Jan;14(1):7-12
pubmed: 23212475
Curr Opin Physiol. 2021 Feb;19:10-16
pubmed: 32728653
J Biomed Biotechnol. 2011;2011:473983
pubmed: 22190852
J Clin Invest. 2019 Jun 17;129(7):2824-2840
pubmed: 31205031
World J Gastroenterol. 2017 Feb 28;23(8):1450-1457
pubmed: 28293092
Gastroenterology. 2016 Oct;151(4):616-32
pubmed: 27436072
J Cell Biol. 1997 Jan 27;136(2):331-43
pubmed: 9015304
Biol Cell. 2017 Apr;109(4):162-166
pubmed: 28186323
Mol Biol Cell. 2015 Mar 1;26(5):887-900
pubmed: 25568343
Biochim Biophys Acta Mol Cell Res. 2017 Jul;1864(7):1183-1194
pubmed: 28322932
Gastroenterol Clin North Am. 2020 Dec;49(4):791-807
pubmed: 33121696
Nat Rev Immunol. 2009 Nov;9(11):799-809
pubmed: 19855405
Curr Opin Cell Biol. 2016 Oct;42:52-62
pubmed: 27131272
J Biomed Biotechnol. 2010;2010:484987
pubmed: 20011071
Cell Tissue Res. 2013 Dec;354(3):783-92
pubmed: 24036843
Br J Cancer. 2016 Mar 1;114(5):545-53
pubmed: 26867158
Microvasc Res. 2009 Jan;77(1):64-9
pubmed: 19232242
Cytoskeleton (Hoboken). 2015 Jul;72(7):362-71
pubmed: 26235381
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Mol Biol Cell. 2017 Feb 15;28(4):524-534
pubmed: 27974639
Nucleic Acids Res. 2020 Jan 8;48(D1):D296-D306
pubmed: 31680160
J Vis Exp. 2017 Jan 5;(119):
pubmed: 28117803
Mucosal Immunol. 2017 Sep;10(5):1237-1247
pubmed: 28120846
J Biol Chem. 2004 Aug 6;279(32):34062-70
pubmed: 15159390
J Cell Biol. 1999 Dec 13;147(6):1351-63
pubmed: 10601346
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9477-9482
pubmed: 32300016
RNA. 2010 Feb;16(2):450-61
pubmed: 20040593
Chem Biol. 2013 May 23;20(5):701-12
pubmed: 23623350
Front Cell Dev Biol. 2021 Feb 01;9:634708
pubmed: 33598464
Cell Mol Gastroenterol Hepatol. 2017 Mar 23;4(1):33-46
pubmed: 28560287
Eur J Surg Oncol. 2019 May;45(5):769-775
pubmed: 30416079
J Biol Chem. 2015 Feb 6;290(6):3238-47
pubmed: 25527498
J Vis Exp. 2016 Jul 13;(113):
pubmed: 27501188
Mol Biol Cell. 2012 Dec;23(23):4601-10
pubmed: 23051739
Nature. 2013 Nov 14;503(7475):281-4
pubmed: 24132237
PLoS One. 2013 May 03;8(5):e61944
pubmed: 23671580

Auteurs

Sandra Chánez-Paredes (S)

Department of Molecular Biomedicine, CINVESTAV-IPN, Mexico City, Mexico.

Armando Montoya-García (A)

Department of Molecular Biomedicine, CINVESTAV-IPN, Mexico City, Mexico.

Karla F Castro-Ochoa (KF)

Department of Molecular Biomedicine, CINVESTAV-IPN, Mexico City, Mexico.

Julio García-Cordero (J)

Department of Molecular Biomedicine, CINVESTAV-IPN, Mexico City, Mexico.

Leticia Cedillo-Barrón (L)

Department of Molecular Biomedicine, CINVESTAV-IPN, Mexico City, Mexico.

Mineko Shibayama (M)

Department of Infectomics and Molecular Pathogenesis, CINVESTAV-IPN, Mexico City, Mexico.

Porfirio Nava (P)

Department of Physiology, Biophysics and Neurosciences, CINVESTAV-IPN, Mexico City, Mexico.

Sven Flemming (S)

Department of Surgery I, University Hospital Würzburg, Würzburg, Germany.

Nicolas Schlegel (N)

Department of Surgery I, University Hospital Würzburg, Würzburg, Germany.

Alexis M Gautreau (AM)

CNRS UMR 7654, Institut Polytechnique de Paris, Palaiseau, France.

Hilda Vargas-Robles (H)

Department of Molecular Biomedicine, CINVESTAV-IPN, Mexico City, Mexico.

Ricardo Mondragón-Flores (R)

Department of Biochemistry, CINVESTAV-IPN, Mexico City, Mexico.

Michael Schnoor (M)

Department of Molecular Biomedicine, CINVESTAV-IPN, Mexico City, Mexico.

Classifications MeSH